mRNA modulators (Novation Pharmaceuticals)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NamemRNA modulators (Novation Pharmaceuticals)
Drug Alias Namec-myc and hSSB1 inhibitors (Novation Pharmaceuticals/Cancer Therapeutics)intracellular messenger RNA modulators(Novation Pharmaceuticals)mRNA therapeutics (Novation Pharmaceuticals/Cancer Therapeutics)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMyc proto-oncogene protein inhibitorsHSP70 heat-shock proteins inhibitors
TargetsMyc proto-oncogene proteinHSP70 heat-shock proteins
Therapy Area/IndicationsNerve DegenerationInflammationMetabolic Diseases +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaAustralia and New Zealand
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNovation Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovation Pharmaceuticals IncCancer Therapeutics CRC Pty Ltd
Active IndicationsN/A
Inactive IndicationsNerve DegenerationInflammationMetabolic Diseases +[4] 

Other Information

ATC CodeN/A
Related LinksN/A